5-chloropyrazinamide has been researched along with Tuberculosis, Pulmonary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, JS; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O | 1 |
1 other study(ies) available for 5-chloropyrazinamide and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Mycobacterium tuberculosis; Prodrugs; Pyrazinamide; Tuberculosis, Pulmonary | 2000 |